Regulatory status & access · 05
Wolverine Legal Status, FDA 503A Category, and Compounding Access
Where the BPC-157 TB-500 access record stands today, what is under active FDA review, and how lawful compounded access works — general information, cited to FDA, not advice.
Wolverine legal status: where the FDA 503A category stands now
The Wolverine legal status question — for the BPC-157 TB-500 blend — turns on its two peptides, and that record is in motion. There is genuine forward momentum, and compounding access may expand. The concrete anchor for that momentum is a scheduled event: an FDA Pharmacy Compounding Advisory Committee (PCAC) meeting is set for July 23-24, 2026 to discuss these peptides as candidates for the Section 503A bulks list [12].
That forward motion sits on top of a present-tense fact that has not changed. Both constituents — BPC-157 and TB-500 — are currently in FDA's 503A "Category 2," bulk drug substances FDA has identified as potentially presenting significant safety risks. That placement took effect with the September 29, 2023 update to FDA's nominated-substances list, and Category 2 substances are not within FDA's enforcement-discretion policy for 503A compounding [10]. In plain terms, compounding-pharmacy access to these peptides is restricted as the record stands today.
Nothing here states that any reclassification has happened. The July 2026 meeting is a scheduled discussion of substances under evaluation — a step in the process, not a decision, a listing, or a settled outcome [12]. This page is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply anything.
What "Category 2" means under Sections 503A and 503B
Two sections of the Federal Food, Drug, and Cosmetic Act govern compounding. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight [11].
A compounder may use a bulk drug substance — an active ingredient used as a starting material, rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. Substances not yet listed are evaluated through a public nomination process [11].
Under FDA's interim policy, Category 2 bulk drug substances are those nominated with enough information to evaluate but which FDA identified as raising significant safety risks. Category 2 is not covered by the enforcement-discretion policy that applies to Category 1, and FDA stated it would consider taking action against a compounder using a Category 2 substance [10]. On January 7, 2025, FDA finalized a revised interim policy under which it no longer sorts newly nominated substances into these numbered categories; substances already in Category 2 are not afforded enforcement discretion even if nominations are updated [11]. Neither BPC-157 nor TB-500 is an FDA-approved drug — a separate question from compounding eligibility [11].
Which Wolverine peptides are under FDA review — and there is no carve-out
Both of Wolverine's components are on the July 2026 agenda; there is no component exception. FDA's public calendar lists BPC-157 and TB-500 (alongside KPV and MOTS-c) as bulk drug substances "being considered for inclusion on the 503A Bulks List" at the scheduled July 23-24, 2026 PCAC meeting [12].
That means the entire pairing is currently Category 2, and the entire pairing is under this one scheduled review. BPC-157 appears as "BPC-157 (free base)" and "BPC-157 acetate" [10]. TB-500 is the substance FDA lists as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — FDA's own entry establishes that the marketed TB-500 is the LKKTETQ fragment of thymosin beta-4 [10]. Both placements took effect with the September 29, 2023 list update, citing concerns including potential immunogenicity for certain routes of administration and complexities with peptide impurities and active-ingredient characterization [10].
Being discussed by PCAC is a step in evaluation, not a final listing decision, and the outcome of the meeting is unknown — no result should be assumed or dated [12].
How legally compounded peptide access works
In the U.S., a legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription [11]. The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, sourced from an FDA-registered 503B outsourcing facility [11].
Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued. It is one route to a licensed-prescriber consultation — not a separate legal status. Telehealth does not expand which substances may be compounded, and it does not remove the need for a legitimate clinical evaluation and a valid prescription [11].
The ingredient-eligibility caveat is the part that matters most for these two peptides. A compounded preparation may lawfully be made only when its active ingredient is permitted under the 503A/503B framework — a USP/NF monograph, a component of an approved drug, or a place on the applicable FDA bulks list. Ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands [11]. As the record stands today, that is where BPC-157 and TB-500 sit. This page does not name any pharmacy, clinic, telehealth provider, or vendor, and offers no dosing, administration instructions, or means of obtaining a restricted substance outside the lawful framework.